![PRD_000183 PRD_000183](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000183.svg) | PRD_000183 | Name: | Microcin C7 | Formula: | C28 H49 N12 O10 S | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002489 PRD_002489](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002489.svg) | PRD_002489 | Name: | lipid II mimetic, LPATA: Thr-in conformation | Formula: | C53 H85 N14 O16 | Definition date: | 2022-09-07 | Last modified: | 2023-11-03 |
|
![PRD_000198 PRD_000198](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000198.svg) | PRD_000198 | Name: | BETA LICHENICIDIN PREPEPTIDE | Formula: | C133 H200 N36 O37 S4 | Description: | LICHENICIDIN VK21 IS A TETRACYCLIC PEPTIDE. POST TRANSLATIONAL
MATURATION OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR, AND
SER INTO DEHYDRATED AMINO ACIDS AND THE FORMATION OF THIOETHER BONDS
WITH CYSTEINE. THIOETHER BONDS WITH CYSTEINE RESULT IN FOUR RINGS.
THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND CLEAVAGE OF THE
MODIFIED PRECURSOR. | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_002510 PRD_002510](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002510.svg) | PRD_002510 | Name: | Minihepcidin PR73 | Formula: | C86 H136 N21 O15 S | Definition date: | 2022-12-07 | Last modified: | 2023-11-03 |
|
![PRD_000213 PRD_000213](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000213.svg) | PRD_000213 | Name: | motuporin | Formula: | C40 H57 N5 O10 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000224 PRD_000224](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000224.svg) | PRD_000224 | Name: | Polytheonamide B | Formula: | C219 H376 N60 O72 S | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_001041 PRD_001041](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001041.svg) | PRD_001041 | Name: | TMC-95A mimic ligand yCP:4e | Formula: | C61 H83 N9 O10 | Definition date: | 2013-05-01 | Last modified: | 2023-11-03 |
|
![PRD_001044 PRD_001044](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001044.svg) | PRD_001044 | Name: | TMC-95A mimic ligand yCP:3a | Formula: | C60 H80 N8 O11 | Definition date: | 2013-05-01 | Last modified: | 2023-11-03 |
|
![PRD_001047 PRD_001047](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001047.svg) | PRD_001047 | Name: | (2E,4E)-N-[(2R,3S)-1-{[(5S,8S,9E)-2,7-dioxo-5-(propan-2-yl)-1,6-diazacyclododec-9-en-8-yl]amino}-3-hydroxy-1-oxobutan-2-yl]dodeca-2,4-dienamide | Formula: | C29 H48 N4 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_001049 PRD_001049](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001049.svg) | PRD_001049 | Name: | TMC-95A mimic ligand yCP:4a chain Q | Formula: | C55 H72 N8 O9 | Definition date: | 2013-05-01 | Last modified: | 2023-11-03 |
|
![PRD_001066 PRD_001066](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001066.svg) | PRD_001066 | Name: | Muramyl tetrapeptide | Formula: | C30 H53 N8 O13 | Definition date: | 2014-03-12 | Last modified: | 2023-11-03 |
|
![PRD_001069 PRD_001069](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001069.svg) | PRD_001069 | Name: | N-acetyl-L-alanyl-L-alanyl-N-[(2S)-1-hydroxypropan-2-yl]-L-prolinamide | Formula: | C16 H28 N4 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000292 PRD_000292](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000292.svg) | PRD_000292 | Name: | BETA-SECRETASE INHIBITOR NVP-AMK640 | Formula: | C29 H50 N6 O10 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_001075 PRD_001075](https://data.pdbj.org/pdbjplus/data/cc/svg/P3N.svg) | PRD_001075 | Name: | N-[(2S)-3-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-1-({(2S)-1-[(4-methylbenzyl)amino]-1-oxo-4-phenylbutan-2-yl}amino)-1-oxopropan-2-yl]-5-methyl-1,2-oxazole-3-carboxamide | Formula: | C32 H38 N6 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000330 PRD_000330](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000330.svg) | PRD_000330 | Name: | (5S,8R,11S)-8-(2-carboxyethyl)-5-(carboxymethyl)-14-(4-ethoxy-4-oxobutanoyl)-11-(1-methylethyl)-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,13,14-pentaazahexadecan-16-oic acid | Formula: | C30 H41 N5 O14 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000332 PRD_000332](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000332.svg) | PRD_000332 | Name: | Cbz-Asp-Glu-Val-AAsp-CHCH-CON(CH3)CH2Ph | Formula: | C36 H46 N6 O13 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_001125 PRD_001125](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001125.svg) | PRD_001125 | Name: | Peptide ligand | Formula: | C51 H75 N9 O14 | Definition date: | 2013-12-04 | Last modified: | 2023-11-03 |
|
![PRD_001157 PRD_001157](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001157.svg) | PRD_001157 | Name: | Ser-Leu-Phe-His-Phenylalanyl-reduced-peptide-bond-Tyrosyl-Thr-Pro | Formula: | C51 H69 N10 O11 | Definition date: | 2014-01-15 | Last modified: | 2023-11-03 |
|
![PRD_000387 PRD_000387](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000387.svg) | PRD_000387 | Name: | N-(tert-butoxycarbonyl)-L-alanyl-L-alanyl-N-{(1R)-1-[(S)-[(1S)-2-{[(1R)-1-carboxyethyl]amino}-1-methyl-2-oxoethoxy](hydroxy)phosphoryl]-2-methylpropyl}-L-prolinamide | Formula: | C26 H46 N5 O11 P | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_000395 PRD_000395](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000395.svg) | PRD_000395 | Name: | ACE-HAC-ARG-MAA-HAQ-SEL | Formula: | C37 H58 N9 O8 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
![PRD_001184 PRD_001184](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001184.svg) | PRD_001184 | Name: | Dimethyl FK228 | Formula: | C26 H42 N4 O6 S2 | Description: | DIMETHYL FK228 IS THE REDUCED AND MODIFIED FORM OF ROMIDEPSIN. THE DISULFIDE INTRAMOLECULAR LINKAGE OF ROMIDEPSIN IS BROKEN, AND BOTH SULFHYDRYL GROUPS ARE METHYLATED. | Definition date: | 2014-03-05 | Last modified: | 2023-11-03 |
|
![PRD_001189 PRD_001189](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001189.svg) | PRD_001189 | Name: | ATSP-7041 stapled-peptide | Formula: | C87 H124 N16 O22 | Definition date: | 2013-11-20 | Last modified: | 2023-11-03 |
|
![PRD_001198 PRD_001198](https://data.pdbj.org/pdbjplus/data/cc/svg/3VH.svg) | PRD_001198 | Name: |
(3aR,5aS,8S,10aS)-1-[(3S,6R,8aS)-1'-[(2S)-2-acetamido-3-(2-chlorophenyl)propanoyl]-5-oxidanylidene-spiro[1,2,3,8a-tetrahydroindolizine-6,2'-pyrrolidine]-3-yl]carbonyl-10-oxidanylidene-2,3,3a,5a,8,10a-hexahydrodipyrrolo[3,2-b:3',1'-f]azepine-8-carboxylic acid | Formula: | C35 H38 Cl N5 O7 | Definition date: | 2014-10-15 | Last modified: | 2023-11-03 |
|
![PRD_001215 PRD_001215](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001215.svg) | PRD_001215 | Name: | Macrocyclic Inhibitor (3R,6S,9S,12E,16S)-9-(3-AMINO-3-OXO-PROPYL)-3-[(4-BENZOYLPHENYL)METHYL]-6-(CYCLOHEXYLMETHYL)-2,5,8,11,14-PENTAOXO-1,4,7,10,15-PENTAZACYCLOICOS-12-ENE-16-CARBOXAMIDE | Formula: | C40 H48 N7 O9 | Definition date: | 2014-05-21 | Last modified: | 2023-11-03 |
|
![PRD_000456 PRD_000456](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000456.svg) | PRD_000456 | Formula: | C39 H67 N12 O10 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|